Friday, August 16, 2019 11:01:23 AM
Literal "Poopy" DD. Nice work.
Restore the endothelial barrier and then we can judge. Figure 2E below is my favorite DD on the web for those that have not seen it. Left picture is normal barrier, middle is damaged, right is repaired. Had to do a double take first time I saw it. Some want to improve the poop bacteria and some want to get ahead of that issue and maintain the barrier. Difference is in research of "wanting" vs photographic evidence IMO
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652299/
Keep healthy endogenous brain enzymes such as BDNF and the body can maintain sleep health. Journal of Sleep Research from last year article below. Been linked here before of course. Notice the last sentence regarding REM sleep and its role in neuroplasticity. Notice its research in an actual trial designed to measure sleep. Fact is that if the neurons never die, sleep doesn't become an issue.
J Sleep Res. 2018 Feb;27(1):73-77. doi: 10.1111/jsr.12577. Epub 2017 Jun 28.
Serum brain-derived neurotrophic factor (BDNF) in sleep-disordered patients: relation to sleep stage N3 and rapid eye movement (REM) sleep across diagnostic entities.
Deuschle M1, Schredl M1, Wisch C1, Schilling C1, Gilles M1, Geisel O2, Hellweg R2.
Abstract
Experimental and clinical evidence suggests an association between neuroplasticity, brain-derived neurotrophic factor and sleep. We aimed at testing the hypotheses that brain-derived neurotrophic factor is associated with specific aspects of sleep architecture or sleep stages in patients with sleep disorders. We included 35 patients with primary insomnia, 31 patients with restless legs syndrome, 17 patients with idiopathic hypersomnia, 10 patients with narcolepsy and 37 healthy controls. Morning serum brain-derived neurotrophic factor concentrations were measured in patients and controls. In patients, blood sampling was followed by polysomnographic sleep investigation. Low brain-derived neurotrophic factor levels were associated with a low percentage of sleep stage N3 and rapid eye movement sleep across diagnostic entities. However, there was no difference in brain-derived neurotrophic factor levels between diagnostic groups. Our data indicate that serum levels of brain-derived neurotrophic factor, independent of a specific sleep disorder, are related to the proportion of sleep stage N3 and REM sleep. This preliminary observation is in accordance with the assumption that sleep stage N3 is involved in the regulation of neuroplasticity.
https://www.ncbi.nlm.nih.gov/pubmed/28656632
Restore the endothelial barrier and then we can judge. Figure 2E below is my favorite DD on the web for those that have not seen it. Left picture is normal barrier, middle is damaged, right is repaired. Had to do a double take first time I saw it. Some want to improve the poop bacteria and some want to get ahead of that issue and maintain the barrier. Difference is in research of "wanting" vs photographic evidence IMO
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652299/
Keep healthy endogenous brain enzymes such as BDNF and the body can maintain sleep health. Journal of Sleep Research from last year article below. Been linked here before of course. Notice the last sentence regarding REM sleep and its role in neuroplasticity. Notice its research in an actual trial designed to measure sleep. Fact is that if the neurons never die, sleep doesn't become an issue.
J Sleep Res. 2018 Feb;27(1):73-77. doi: 10.1111/jsr.12577. Epub 2017 Jun 28.
Serum brain-derived neurotrophic factor (BDNF) in sleep-disordered patients: relation to sleep stage N3 and rapid eye movement (REM) sleep across diagnostic entities.
Deuschle M1, Schredl M1, Wisch C1, Schilling C1, Gilles M1, Geisel O2, Hellweg R2.
Abstract
Experimental and clinical evidence suggests an association between neuroplasticity, brain-derived neurotrophic factor and sleep. We aimed at testing the hypotheses that brain-derived neurotrophic factor is associated with specific aspects of sleep architecture or sleep stages in patients with sleep disorders. We included 35 patients with primary insomnia, 31 patients with restless legs syndrome, 17 patients with idiopathic hypersomnia, 10 patients with narcolepsy and 37 healthy controls. Morning serum brain-derived neurotrophic factor concentrations were measured in patients and controls. In patients, blood sampling was followed by polysomnographic sleep investigation. Low brain-derived neurotrophic factor levels were associated with a low percentage of sleep stage N3 and rapid eye movement sleep across diagnostic entities. However, there was no difference in brain-derived neurotrophic factor levels between diagnostic groups. Our data indicate that serum levels of brain-derived neurotrophic factor, independent of a specific sleep disorder, are related to the proportion of sleep stage N3 and REM sleep. This preliminary observation is in accordance with the assumption that sleep stage N3 is involved in the regulation of neuroplasticity.
https://www.ncbi.nlm.nih.gov/pubmed/28656632
Recent TAOX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:21:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/02/2026 09:32:45 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/02/2026 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:23:07 PM
- TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation • PR Newswire (US) • 11/18/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2025 09:10:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/07/2025 09:41:16 PM
- TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds • PR Newswire (US) • 11/04/2025 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/24/2025 08:12:47 PM
- TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency • PR Newswire (US) • 10/20/2025 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2025 09:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 10:12:21 AM
- TAO Synergies Announces $11 Million Private Placement • PR Newswire (US) • 10/13/2025 09:09:00 PM
- TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO) • PR Newswire (US) • 09/22/2025 01:15:00 PM
- TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event • PR Newswire (US) • 09/08/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2025 09:00:44 PM
- TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy • PR Newswire (US) • 08/26/2025 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2025 08:51:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 08:50:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 08:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 09:17:38 PM
